Navigation Links
PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
Date:10/27/2009

lts to previous periods and forecasted guidance because such measures exclude items that are outside of the Company's normal operations. Management uses non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for assessing the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above. Such measures are also used by management in its financial and operating decision-making. Non-GAAP financial measures are not meant to be considered superior to or a substitute for the Company's results of operations prepared in accordance with GAAP.

A conference call to discuss PAREXEL's financial results, and business and financial outlook will begin at 10:00 a.m. EDT on Wednesday, October 28, 2009 and will be broadcast live over the internet via webcast. The webcast may be accessed in the "Webcasts" portion of the Investors section of the Company's website at www.PAREXEL.com. Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed. A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event. To participate via telephone, dial +1-706-758-4950 and ask to join PAREXEL's Conference Call.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the dev
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
2. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
3. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
4. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
5. PAREXEL Expands Global Clinical Pharmacology Capabilities
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
8. NxStage(R) Reports Significant Interim FREEDOM Study Results
9. Hospira Reports Third-Quarter 2009 Results
10. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
11. Lilly Reports Solid Third-Quarter 2009 Results; Revises Full-Year 2009 EPS Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS confirma su posición en un entorno difícil 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3
(Date:12/20/2014)... (PRWEB) December 20, 2014 Developers of ... release of a new plugin for Final Cut Pro ... , “TranSlice Volume 5 allows users to create hand ... it.” Said Christina Austin, CEO of Pixel Film Studios. ... of professionalism while maintaining an easy to use interface.” ...
(Date:12/20/2014)... December 20, 2014 Today, Balfleet.com, one ... a Christmas Sale, offering 50%-70% off on its ... season. , The mother of the bride dresses from ... company is 24/7 accessible and takes pride in providing ... , “We are offering great discounts on our mother ...
(Date:12/19/2014)... Sub Zero Ice Cream is partnering up with ... the 28th from 2pm-6pm at the Expo Center on the ... FL. , Inquiries regarding time slots and signing up, email ... donating process, Sub Zero Ice Cream & Yogurt will be ... , About Sub Zero Ice Cream & Yogurt , ...
(Date:12/19/2014)... CA (PRWEB) December 19, 2014 SuperCloset ... 5x5 SuperClone Rooms. SuperCloset continues to offer indoor growers ... Pair one of the new SuperClone Rooms with the ... perpetual, and turnkey indoor hydroponic grow room setup. , ... the world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... TX (PRWEB) December 20, 2014 The ... a new injectable filler from respected cosmetic brand Juvéderm. ... occur naturally with age. The Medspa at Hendrick is ... development in skin care technology to its clients. , ... gel to be FDA-approved to treat the mid-face and ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2Health News:Balfleet.com is Offering 50%-70% Off of its Mother of the Bride Dresses 2Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2
... Greater International Representation, WASHINGTON, Aug. 12 ... participation of 37 Supporting Partner,Organizations from around ... Zealand, Russia and the United Kingdom, as ... in the U.S. These Supporting Partner,Organizations have ...
... Investment Trust Inc.,(NYSE: CRE ) ("Care"), a real ... and commercial mortgage debt,today announced an agreement in principle ... terms:, -- Care will receive an option to ... mortgage assets on an individual basis at any time ...
... The development and repair of heart tissue and blood ... ribonucleic acid (RNA) that is found nowhere else in ... found. , Because of its specificity to the cardiovascular ... therapeutic treatment, the researchers said. , "Manipulating this microRNA ...
... N.J., Aug. 12 Barr Pharmaceuticals,Inc. (NYSE: ... Barr Laboratories subsidiary has,signed a Settlement Agreement ... resolve the patent litigation involving Boehringer Ingelheim,s,Mirapex(R) ... Settlement,Agreement and a Supply Agreement to resolve ...
... the release of Sfetyworks™, a web-based, semi-automated ... quickly spot and measure the strength of ... condition found within large electronic healthcare databases. ... plc (GSK) and ProSanos. Several years in ...
... Ind., Aug. 12 Hillenbrand, Inc.,(NYSE: HI ... consistent,with $165.6 million reported in the third quarter ... third-quarter earnings per share, operating,profit and cash flow ... for the quarter remained essentially flat, even as ...
Cached Medicine News:Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 2Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 3Health News:AdvaMed 2008 Supporting Partner Organizations Up 30% Over Last Year 4Health News:Care Investment Trust Inc. Announces an Agreement in Principle for CIT Healthcare to Purchase Mortgage Assets and Reduce Management Fee 2Health News:Tiny molecule helps control blood-vessel development, UT Southwestern researchers find 2Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 2Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 3Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 4Health News:Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges 5Health News: ProSanos Corporation Releases New Software System to Improve Patient Safety via Surveillance and Analysis of Claims and Electronic Health Records 2Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 2Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 3Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 4Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 5Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 6Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 7Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 8Health News:Hillenbrand, Inc. Reports Third-Quarter Revenue of $165 Million and Earnings Per Share of $0.42 9
... e-power series power supplies are ... gel electrophoresis system. These units ... the most rigorous safety standard, ... the most compact and powerful ...
... ZOOM® Dual Power is a microprocessor-controlled ... both high voltage/low current and high ... voltage/low current section is ideal for ... DNA sequencing applications. The low voltage/high ...
... These modified battery chargers ... supplies for GENIE blotters. ... produce very specific voltages, ... than laboratory power supplies. ...
... These modified battery ... power supplies for GENIE ... to produce very specific ... reproducibility than laboratory power ...
Medicine Products: